About
Stella (Yibin) Shi is the founder, Chief Executive Officer, and board chair of Rona Therapeutics, a Shanghai-based RNA therapeutics company focused on metabolic and degenerative diseases. Rona says she previously served as a managing director at Lilly Asia Ventures and brought roughly 15 years of biopharmaceutical and venture-capital experience to the company’s 2021 launch. Under her leadership, Rona has raised multiple venture rounds to advance siRNA programs in cardiometabolic, obesity, kidney, and neurodegenerative indications.
Areas of interest
biotechRNA therapeuticssiRNAcardiometabolic diseaseobesityMASHneurodegenerative diseasedrug discoveryventure capital